Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Nab-POF in Gastric Cancer
NCT04510064Phase 2Completed
- Sponsor
- Fudan University
- Start
- Jan 2021
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Fudan University. Started Jan 2021; status: completed.
02
Drugs
camrelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04510064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510064.